ClinicalTrials.gg
RecruitingNCT06704334Updated Aug 17, 2026

The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury

A Phase 4 interventional study of Median nerve electrical stimulation treatment and Huperzine A injection in Cognitive Impairment After Brain Injury, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Brain Injuries with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Brain Injuries · China.

Planned enrollment
16th of 23
50 · median 96
Started
2024
with 10 others
Phase 4
5 of 47
3 open now
Primary completion
2026-12
later than 10 of 17 live
Registered
29th of 47
by date

Among the 47 studies in Brain Injuries with a site in China, this one is the 16th largest by planned enrollment of the 23 interventional ones that give a count, is one of 11 that started in 2024, is one of 5 in phase 4, reaches primary completion later than 10 of the 17 other live ones, and was the 29th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 236 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

17 of the 47 studies in Brain Injuries with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 153 Brain Injuries studies recruiting now, 76 (50%) set no upper age limit and 55 (36%) stop at 75 or younger; 39 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Brain Injuries with a site in China, or all of them as a file.
02

Study summary

This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.

Read the detailed description

Specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.

03

Conditions studied

  • Cognitive Impairment After Brain Injury
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be over 18 years old
  • Residual cognitive impairment due to brain injury
  • No previous history of brain-related diseases except this one

Exclusion criteria

Exclusion Criteria:

  • The patient had severe underlying disease and unstable vital signs
  • The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment
  • Allergic to drugs or in drug use
  • There are contraindications of median nerve electrical stimulation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Median nerve electrical stimulation group

    The optimal median nerve electrical stimulation treatment was given

    Other: Median nerve electrical stimulation treatment

  • Experimental
    Huperzine A injection + median nerve electrical stimulation group

    Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days.

    Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection

  • Experimental
    Huperzine A injection + median nerve electrical stimulation + Ginkgo leaf dropping pill group

    Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. After the end of the electrical stimulation treatment, ginkgo biloba dropping pills were given as long-term administration to maintain the therapeutic effect. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days. Ginkgo leaf dropping pills: Oral, each pill weighs 63mg, 5 pills/time, 3 times/day, the course of treatment is 3 months.

    Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection · Drug: Ginkgo leaf dropping pill

Interventions

  • OtherMedian nerve electrical stimulation treatment

    Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.

  • intramuscular

  • DrugGinkgo leaf dropping pill

    oral

06

What researchers measure

Primary outcomes

  1. to assess the Mini-Mental State Examination (MMSE) score

    Mini-Mental State Examination (MMSE): total score ranges from 0 to 30. Higher scores indicate better cognitive function.

    Time frame: baseline,Day10,Day90

Secondary outcomes

  1. to assess the Montreal Cognitive Assessment (MoCA) score

    Montreal Cognitive Assessment (MoCA): total score ranges from 0 to 30. Higher scores indicate better cognitive function.

    Time frame: baseline,Day10,Day90

  2. to assess the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) score

    Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog): total score ranges from 0 to 70. Higher scores indicate worse cognitive performance.

    Time frame: baseline,Day10,Day90

  3. to assess the Hamilton Depression Rating Scale (HAMD) score

    Hamilton Depression Rating Scale (HAMD-24 item): total score ranges from 0 to 76. Higher scores indicate more severe depressive symptoms.

    Time frame: baseline,Day10,Day90

  4. to assess the Hamilton Anxiety Rating Scale (HAMA) score

    Hamilton Anxiety Rating Scale (HAMA): total score ranges from 0 to 56. Higher scores indicate more severe anxiety symptoms.

    Time frame: baseline,Day10,Day90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
Nov 26, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704334
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Collaborators
Ganzhou City People's Hospital
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Apr 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 17, 2026

Study contacts

Dong Wang
Contact
2623693068@qq.com
18007076858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huperzine A

Start the discussion